Pathos AI Raises $237M at $3B Valuation
Pathos AI raised $237M at a $3B valuation in a Series E led by Bristol Myers Squibb, pairing with Tempus AI to build AI tools for Alzheimer's drug discovery.
Pathos AI announced Friday that it has raised $237 million in a Series E funding round led by drugmaker Bristol Myers Squibb, valuing the New York-based company at about $3 billion. Existing investors also joined the round. Alongside the raise, Pathos revealed a three-way collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.
The funding round
Bristol Myers Squibb led the $237 million Series E, which valued Pathos AI at about $3 billion. The company said the proceeds will be used to further scale the capabilities of its Pathos Foundry AI platform and to accelerate its AI-driven drug pipeline, including its experimental cancer drug JSKN016.
A three-way AI drug bet
The collaboration splits the work three ways: - Tempus AI will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology. - Pathos will license that data under a five-year, $55 million agreement, then apply its Pathos Foundry platform to study the dataset at scale, generate and test hypotheses on disease biology, and design more targeted, adaptive clinical trials. - Bristol Myers Squibb will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, plus three-year exclusive rights to use the platform for its neuroscience development programs.
What Foundry is building
Pathos Foundry is the company's AI platform for drug development. CEO Iker Huerga has framed it as a system built to improve the probability of success in drug development, and the funding will push its pipeline forward. Current cancer programs include: - JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate, which the company wants to move toward registrational studies. - Pocenbrodib, being tested in metastatic castration-resistant prostate cancer and relapsed or refractory multiple myeloma. - AZD4241, an ER PROTAC for ER-positive breast cancer, developed in partnership with AstraZeneca. - DO-2, a next-generation MET kinase inhibitor for MET-altered lung cancer.
Why big pharma wants in
Alzheimer's has been one of the hardest areas in medicine, with many costly trial failures. Bristol Myers Squibb says it hopes AI insights will help it understand disease progression and find the patients most likely to benefit from new treatments. The deal fits a wider trend of drugmakers teaming up with AI firms as they hunt for faster, cheaper ways to develop drugs.
What comes next
Pathos plans to keep expanding Foundry and push JSKN016 toward registrational studies, while the Tempus dataset grows into one of the largest long-term neurological datasets in the industry. If the platform delivers, it could change how early drug research is done. But the real test, as with every biotech bet, is whether its drugs actually win approval.
Sources
- Reuters - https://www.reuters.com/legal/litigation/pathos-ai-teams-up-with-bristol-myers-tempus-ai-advance-drug-development-2026-10-23/ - AI Parabellum - https://aiparabellum.com/pathos-ai-237m-series-e-drug-development/